Abstract
Get full access to this article
View all access options for this article.
References
1.
Califf
RM
. Clinical trials bureaucracy: unintended consequences of well-intentioned policy . Clin Trials . 2006 ;3 :496 –502 .
2.US Food and Drug Administration . Pharmaceutical quality for the 21st century: a risk-based approach progress report . March 9, 2010 . http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm128080.htm. Accessed October 1, 2012 .
3.International Conference on Harmonisation (ICH)
of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: quality risk management Q9, current step 4 version (ICHQ9). November 2005 . http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf. Accessed October 1, 2012 .
4.
Morrison
B
Behrman
R
Landray
M
;
on behalf of Clinical Trials Transformation Initiative Monitoring Project . Results and recommendations: effective and efficient monitoring as a component of quality assurance in the conduct of clinical trials. May 20, 2011 . https://www.ctti-clinicaltrials.org/project-topics/study-quality/effective-and-efficient-monitoring-as-a-component-of-quality/results-and-recommendations. Accessed October 1, 2012 .
5.US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), and Center for Devices and Radiological Health (CDRH). Guidance for industry: oversight of clinical investigations—a risk-based approach to monitoring. August 29, 2011
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM269919.pdf. Accessed October 1, 2012 .